Table 1.

Decrease percentage of monomeric bevacizumab (BVZ) concentration (ΔC%) in normal saline and in a vehicle (an aqueous solution with the same composition of the commercial product).

Initial Concentration	1.25 mg/mL	5 mg/mL	1.25 mg/mL	5 mg/mL
Time (Days)	ΔC% in Normal Saline		ΔC% in a Vehicle
1	−24	−10	0	0
4	−30	−12	0	0
30	−33	−14	−1.8	−1.2